[The new biomarkers of prostate cancer]

Biomarkers of prostate cancer can assess a presence risk or an evolution risk of the disease. The integration of temporal and clinical data during the interpretation of a PSA dosage improves its performance. Trough a performing algorithm, the Phi index (Prostate Health Index) combines the results of total PSA, free PSA, and pro-PSA. The ration of urinary PCA3 and urinary PSA determines a powerful marker to be used in difficult diagnostic situations. Gene fusions in prostate cancer are promising biomarkers and eventual therapeutic targets. The cost of these new biomarkers is limiting their current use to individual situations.